ニュース
Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...
Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...
Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...
Biosimilar FYB202 or ustekinumab-aauz (Otulfi; Fresenius Kabi) had no clinically relevant effect on efficacy, safety, or immunogenicity and demonstrated therapeutic equivalence to reference ...
A French observational study found “high acceptance levels” among patients with inflammatory bowel disease (IBD) offered a switch from the adalimumab reference product to 1 of 5 biosimilars when also ...
Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する